{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:46:15Z","timestamp":1790703975556,"version":"4.1.0"},"reference-count":43,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2015,11,30]],"date-time":"2015-11-30T00:00:00Z","timestamp":1448841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>There is a paucity of strong evidence associated with adverse pregnancy outcomes and thrombophilia in pregnancy. These problems include both early (recurrent miscarriage) and late placental vascular-mediated problems (fetal loss, pre-eclampsia, placental abruption and intra-uterine growth restriction). Due to poor quality case-control and cohort study designs, there is often an increase in the relative risk of these complications associated with thrombophilia, particularly recurrent early pregnancy loss, late fetal loss and pre-eclampsia, but the absolute risk remains very small. It appears that low-molecular weight heparin has other benefits on the placental vascular system besides its anticoagulant properties. Its use is in the context of antiphospholipid syndrome and recurrent pregnancy loss and also in women with implantation failure to improve live birth rates. There is currently no role for low-molecular weight heparin to prevent late placental-mediated complications in patients with inherited thrombophilia and this may be due to small patient numbers in the studies involved in summarising the evidence. There is potential for low-molecular weight heparin to improve pregnancy outcomes in women with prior severe vascular complications of pregnancy such as early-onset intra-uterine growth restriction and pre-eclampsia but further high quality randomised controlled trials are required to answer this question.<\/jats:p>","DOI":"10.3390\/ijms161226104","type":"journal-article","created":{"date-parts":[[2015,11,30]],"date-time":"2015-11-30T10:57:24Z","timestamp":1448881044000},"page":"28418-28428","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Thrombophilia and Pregnancy Complications"],"prefix":"10.3390","volume":"16","author":[{"given":"Louise","family":"Simcox","sequence":"first","affiliation":[{"name":"Maternal and Fetal Health Research Centre, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Hathersage Road, Manchester M13 9WL, UK"},{"name":"St. Mary\u2019s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ormesher","sequence":"additional","affiliation":[{"name":"St. Mary\u2019s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Tower","sequence":"additional","affiliation":[{"name":"Maternal and Fetal Health Research Centre, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Hathersage Road, Manchester M13 9WL, UK"},{"name":"St. Mary\u2019s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Greer","sequence":"additional","affiliation":[{"name":"The University of Manchester, Oxford Road, Manchester M13 9PL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1160\/TH09-10-0704","article-title":"Haemostatic reference intervals in pregnancy","volume":"103","author":"Szecsi","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_2","first-page":"490","article-title":"Activation of coagulation in amniotic fluid during normal human pregnancy","volume":"128","author":"Sarig","year":"2011","journal-title":"Thromb. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2012.05.027","article-title":"Tissue factor-dependent thrombin generation across pregnancy","volume":"207","author":"McLean","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa1311485","article-title":"Risk of a thrombotic event after the 6-week postpartum period","volume":"370","author":"Kamel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2013-01-478958","article-title":"Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications","volume":"123","author":"Rodger","year":"2014","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjh.12813","article-title":"Antithrombotic treatment for pregnancy complications: Which path for the journey to precision medicine?","volume":"165","author":"Greer","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1000292","DOI":"10.1371\/journal.pmed.1000292","article-title":"The association of factor. V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: A systematic review and meta-analysis of prospective cohort studies","volume":"7","author":"Rodger","year":"2010","journal-title":"PLoS Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1538-7836.2012.04773.x","article-title":"Thrombophilias and adverse pregnancy outcomes: Results from the Danish National Birth Cohort","volume":"10","author":"Lykke","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2005.05847.x","article-title":"Thrombophilia in pregnancy: A systematic review","volume":"132","author":"Robertson","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/jth.12509","article-title":"Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study","volume":"12","author":"Rodger","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1576\/toag.13.1.15.27636","article-title":"Diagnosis and management of antiphospholipid syndrome in pregnancy","volume":"13","author":"Myers","year":"2011","journal-title":"Obstet. Gynaecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0015-0282(16)58565-3","article-title":"Antiphospholipid antibody panels and recurrent pregnancy loss: Prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies","volume":"66","author":"Yetman","year":"1996","journal-title":"Fertil. Steril."},{"key":"ref_13","first-page":"2214","article-title":"Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: A metaanalysis","volume":"33","author":"Opatrny","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2011.02.006","article-title":"The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis","volume":"128","author":"Carrier","year":"2011","journal-title":"Thromb. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e0131606","DOI":"10.1371\/journal.pone.0131606","article-title":"Annexin A5 promoter haplotype M2 is not a risk factor for recurrent pregnancy loss in Northern Europe","volume":"10","author":"Nagirnaja","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1160\/TH09-02-0123","article-title":"Haplotype M2 in the annexin A5 (ANXA5) gene and the occurrence of obstetric complications","volume":"102","author":"Tiscia","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/hmg\/ddm017","article-title":"A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss","volume":"16","author":"Bogdanova","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.placenta.2013.09.010","article-title":"Contribution of fetal ANXA5 gene promoter polymorphisms to the onset of pre-eclampsia","volume":"34","author":"Ota","year":"2013","journal-title":"Placenta"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0143-4004(83)80043-5","article-title":"Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy","volume":"4","author":"Pijnenborg","year":"1983","journal-title":"Placenta"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2012-08-448209","article-title":"Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model","volume":"121","author":"An","year":"2013","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/humupd\/dmn031","article-title":"The potential role of heparin in assisted conception","volume":"14","author":"Nelson","year":"2008","journal-title":"Hum. Reprod. Update"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.fertnstert.2011.07.1095","article-title":"Assessment of endometrial receptivity","volume":"96","author":"Lessey","year":"2011","journal-title":"Fertil. Steril."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nm825","article-title":"The thrombomodulin-protein C system is essential for the maintenance of pregnancy","volume":"9","author":"Isermann","year":"2003","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/14647270801995431","article-title":"Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: A prospective randomized placebo-controlled trial","volume":"11","author":"Qublan","year":"2008","journal-title":"Hum. Fertil."},{"key":"ref_26","first-page":"425","article-title":"Low-molecular-weight heparin in women with repeated implantation failure","volume":"7","author":"Lodigiani","year":"2011","journal-title":"Women\u2019s Health"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Cohen, H., and O\u2019Brien, P. (2012). Disorders of Thrombosis and Hemostasis in Pregnancy, A Guide to Management, Springer-Verlag.","DOI":"10.1007\/978-1-4471-4411-3"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1046\/j.1365-2516.1998.440683.x","article-title":"The management of factor XI deficiency","volume":"4","year":"1998","journal-title":"Haemophil. Off. J. World Fed. Hemophil."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/art.1780310307","article-title":"Lupus pregnancy. A prospective study of placental changes","volume":"31","author":"Hanly","year":"1988","journal-title":"Arthritis Rheum."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Empson, M., Lassere, M., Craig, J., and Scott, J. (2005). Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst. Rev., 2.","DOI":"10.1002\/14651858.CD002859.pub2"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0002-9378(96)70610-5","article-title":"Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone","volume":"174","author":"Kutteh","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"Rai","year":"1997","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00006250-200212000-00032","article-title":"Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment","volume":"100","author":"Farquharson","year":"2002","journal-title":"Obstet. Gynecol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1471-0528.1999.tb08208.x","article-title":"Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin","volume":"106","author":"Backos","year":"1999","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.rbmo.2015.07.004","article-title":"Investigation of the Annexin A5 M2 haplotype in 500 white European couples who have experienced recurrent spontaneous abortion","volume":"31","author":"Demetriou","year":"2015","journal-title":"Reprod. BioMed. Online"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/srep00827","article-title":"Loss of maternal annexin A5 increases the likelihood of placental platelet thrombosis and foetal loss","volume":"2","author":"Ueki","year":"2012","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(96)04125-6","article-title":"Increased fetal loss in women with heritable thrombophilia","volume":"348","author":"Preston","year":"1996","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1000641","article-title":"Aspirin plus heparin or aspirin alone in women with recurrent miscarriage","volume":"362","author":"Kaandorp","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1160\/TH10-05-0334","article-title":"Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: A randomised multicentre trial","volume":"105","author":"Visser","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/M14-2062","article-title":"Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: A multicenter trial with a minimization randomization scheme","volume":"162","author":"Schleussner","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1538-7836.2011.04553.x","article-title":"Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: The FRUIT-RCT","volume":"10","author":"Hague","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1160\/TH11-05-0340","article-title":"Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial","volume":"106","author":"Gris","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(14)60793-5","article-title":"Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): A multinational open-label randomised trial","volume":"384","author":"Rodger","year":"2014","journal-title":"Lancet"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/12\/26104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:53:02Z","timestamp":1760215982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/12\/26104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,30]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["ijms161226104"],"URL":"https:\/\/doi.org\/10.3390\/ijms161226104","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,30]]}}}